argenx to Present at TD Cowen 46th Annual Healthcare Conference
Rhea-AI Summary
argenx (Euronext & Nasdaq: ARGX) announced that Karen Massey, Chief Operating Officer, will speak in a fireside chat at the TD Cowen 46th Annual Healthcare Conference on Monday, March 2, 2026 at 11:50 a.m. ET.
According to the company, a live webcast will be available on the Investors section of the argenx website, with a replay accessible for approximately 30 days after the presentation.
Positive
- None.
Negative
- None.
News Market Reaction – ARGX
In the Feb 23 session, ARGX declined 2.15%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 19 | Earnings date notice | Neutral | +0.1% | Scheduled full-year 2025 results and Q4 update call announcement. |
| Jan 13 | Regulatory update | Positive | +1.8% | FDA acceptance of VYVGART sBLA with Priority Review and set PDUFA date. |
| Jan 12 | Strategic outlook | Positive | +0.9% | Strong 2025 sales, 2026 strategic priorities, and pipeline expansion plans. |
| Jan 06 | Conference appearance | Neutral | +0.4% | Announcement of presentation at J.P. Morgan Healthcare Conference. |
| Jan 05 | Leadership change | Negative | -4.7% | CEO transition and board changes subject to shareholder approval. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news-driven moves have generally aligned with the underlying tone: positive regulatory and strategic updates saw modest gains, while leadership transition news coincided with a larger decline.
Over recent months, ARGX has communicated a series of strategic and regulatory milestones. A leadership transition announcement on Jan 5, 2026 coincided with a -4.66% move, while strong 2025 sales and 2026 priorities reported on Jan 12, 2026 saw the stock up 0.95%. FDA priority review for VYVGART on Jan 13, 2026 was followed by a 1.82% gain. Conference participation announcements and an upcoming earnings date have produced small positive reactions, suggesting routine events typically have limited impact.
AI-generated analysis. How Rhea-AI works. Not financial advice.
February 23, 2026
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karen Massey, Chief Operating Officer, will participate in a fireside chat at the TD Cowen 46th Annual Healthcare Conference on Monday, March 2 at 11:50 a.m. ET.
A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately 30 days following the presentation.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.
Contacts
Media:
Ben Petok
bpetok@argenx.com
Investors:
Alexandra Roy
aroy@argenx.com
